Ruxolitinib, Free Base

Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC50's of 2.7 and 4.5nm for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis. Antineoplastic, anti-inflammatory and immunomodulating agent. Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy.||Synonyms:|(b-R)-b-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INCB018424, INC18424, NCB018424, NCB18424||CAS No:|941678-49-5||Molecular Formula:|C17H18N6||Molecular Weight:|306.37||Appearance:|White to off-white powder||Purity:|≥98% (HPLC, TLC)||Solubility:|Souble in DMSO at 28mg/ml. Soluble in ethanol at 15mg/ml with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-50uM; buffers, serum or other additives may increase or decrease the aqueous solubility.||Storage and Stability:|Powder may be stored at -20°C. Stable for 6 months after receipt at -20°C. Reconstitute with DMSO or EtOH. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Light sensitive.